Attorney Docket P1381R1C1P4 **PATENT** 

Please type a plus sign (+) inside this box +



#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**BOX PATENT APPLICATION Assistant Commissioner of Patents** Washington, D.C. 20231

## NON-PROVISIONAL APPLICATION TRANSMITTAL UNDER 37 CFR 1.53(b)

Transmitted herewith for filing is a non-provisional patent application:

Inventor(s) (or Application "Identifier"):

Jian Chen, **Ellen Filvaroff Sherman Fong Dorothy French Audrey Goddard** Paul J. Godowski Christopher J. Grimaldi **Austin L. Gurney** Kenneth J. Hillan Sarah G. Hymowitz Hanzhong Li James Pan Melissa A. Starovasnik **Daniel Tumas** Menno Van Lookeren **Richard Vandlen** Colin K. Watanabe P. Mickey Williams William I. Wood Daniel G. Yansura

Title:

IL-17 Homologous Polypeptides and Therapeutic Uses Thereof



P1381R1C1P4 Page 2 of 5

#### 1. Type of Application

- [ ] This application is for an original, non-provisional application.
- [ ] This is a non-provisional application claiming priority to provisional application no. \_\_, filed \_\_\_, the entire disclosure of which is hereby incorporated by reference.
- This is a continuation-in-part application which claims priority to U.S. Provisional Application [x] Nos.: 60/253,646 filed November 28, 2000; 60/244,072 filed October 26, 2000; 60/242,837 filed October 24, 2000; 60/213,807 filed June 22, 2000; 60/191,007 filed March 21, 2000, now abandoned; 60/175,481 filed January 11, 2000, now abandoned; 60/172,096 filed December 23, 1999, now abandoned; 60/138,387 filed June 9, 1999, now abandoned; 60/134,287 filed May 14, 1999, now abandoned; 60/131,022 filed April 26, 1999, now abandoned; 60/130,232 filed April 21, 1999, now abandoned; 60/113,621 filed December 23, 1998, now abandoned; 60/085,579 filed May 15, 1998, now abandoned; and to which U.S. Provisional Applications claim priority under 35 U.S.C. §119; and also claims priority to International PCT Application Nos.: PCT/US01/21735 filed July 9, 2001; PCT/US01/21066 filed June 29, 2001; PCT/US01/19692 filed June 20, 2001; PCT/US01/17800 filed June 1, 2001; PCT/US01/06520 filed February 28, 2001; PCT/US00/34956 filed December 20, 2000; PCT/US00/32678 filed December 1, 2000; PCT/US00/30873 filed November 10, 2000; PCT/US00/23328 filed August 24, 2000; PCT/US00/15264 filed June 2, 2000; PCT/US00/07532 filed March 21, 2000; PCT/US00/05841 filed March 2, 2000; PCT/US00/05601 filed March 1, 2000; PCT/US00/04341 filed February 18, 2000; PCT/US99/31274 filed December 30, 1999; PCT/US99/10733 filed May 14, 1999; PCT/US99/05028 filed March 8, 1999; to which International PCT Applications claim priority under 35 U.S.C. §120; and also claims priority to U.S. Patent Application Nos.: 09/931,836 filed August 16, 2001; 09/929,404 fled August 13, 2001; 09/918,585 filed July 30, 2001; 09/908,827 filed July 18, 2001; 09/874,503 filed June 5, 2001; 09/854,280 filed May 10, 2001; 09/854,208 filed May 10, 2001; 09/816,744 filed March 22, 2001; 09/747,259 filed December 20, 2000; 09/644.848 filed August 22, 2000; 09/380,142 filed August 25, 1999; 09/380,138 filed August 25, 1999; 09/311,832 filed May 14, 1999; to which U.S. Patent Applications claim priority under 35 U.S.C. §120., the entire disclosures of which hereby incorporated by reference.

# 2. Papers Enclosed Which Are Required For Filing Date Under 37 CFR 1.53(b) (Non-provisional)

<u>159</u> pages of specification

\_\_9 \_\_ pages of claims

\_\_1\_\_ page of abstract

\_\_70\_ sheet(s) of drawings

[] formal [x] informal

#### 3. Declaration or Oath

	(for new and CIP applications; also for Cont./Div. where inventor(s) are being added)
X	An unsigned declaration of the inventors is enclosed. An executed declaration
	of the inventors will follow.

(for Cont./Div. where inventorship is the same or inventor(s) being deleted)
 A copy of the executed declaration/oath filed in the prior application is enclosed
(37 CFR 1.63(d)).

	<ul> <li>(for Cont./Div. where inventor(s) being deleted)</li> <li>A signed statement is attached deleting inventor(s) named in the prior application (see 37 CFR 1.63(d)(2) and 1.33(b)).</li> </ul>
4.	Assignment
	(for new and CIP applications) x
	(for cont./div.) The prior application is assigned of record to Genentech, Inc.
5.	Amendments (for continuation and divisional applications)
	Cancel in this application original claims of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)
	A preliminary amendment is enclosed. (Claims added by this amendment have been properly numbered consecutively beginning with the number next following the highest numbered original claim in the prior application.)
	Relate Back 35 U.S.C. 120 or 35 U.S.C. 119
	Amend the specification by inserting before the first line the sentence:
	This is a
	non-provisional application continuation divisional continuation-in-part
	of co-pending application(s)
	Serial No filed on_, which application(s) is(are) incorporated herein by reference and to which application(s) priority is claimed under 35 USC §120  International Application _ filed on _ which designated the U.S., which application(s) is(are) incorporated herein by reference and to which application(s) priority is claimed under 35 USC \$120.
	§120 provisional application No filed _, the entire disclosure of which is hereby incorporated by reference and to which application(s) priority is claimed under 35 USC §119

#### 6. Fee Calculation (37 CFR 1.16)

The fee has been calculated as follows:

THETE	o nao boon	Calculated as 10			
		CLAIN	S FOR FEE CA	LCULATION	
Number Filed.		Number Extra		Rate	Basic Fee 37 CFR 1.16(a)
					\$740.00
Total Claims	60	- 20 =	40	X \$18.00	\$720.00
Independent Claims	28	- 3=	25	X \$80.00	\$2,000.00
x Multiple dependent		lependent claim	(s), if any	+ \$270.00	\$270.00
			Fil	ing Fee Calculation	\$3,730.00

#### 7. Method of Payment of Fees

The Commissioner is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$3,730.00. A duplicate copy of this transmittal is enclosed.

### 8. Authorization to Charge Additional Fees

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR §1.16 and 1.17, or credit overpayment to Deposit Account No. 07-0630. <u>A duplicate copy of this sheet is enclosed</u>.

a	<b>Additional</b>	Paners	<b>Enclosed</b>

- Information Disclosure Statement (37 CFR §1.98) w/ PTO-1449 and citations
- Submission of "Sequence Listing", computer readable copy, certificate re: sequence listing, and/or amendment pertaining thereto for biological invention containing nucleotide and/or amino acid sequence.
- A new Power of Attorney or authorization of agent.
- [] Other:

# 10. Maintenance of Copendency of Prior Application (for continuation and divisional applications)

[This item **must** be completed and the necessary papers filed in the prior application if the period set in the prior application has run]

A petition, fee and/or response has been filed to extend the term in
 the pending prior application until
 A copy of the petition for extension of time in the prior application
 is attached.

#### 11. Correspondence Address:

X Address all future communications to:

Attn: Elizabeth M. Barnes

Respectfully submitted, GENENTECH, INC.

Date: October 30, 2001

Elizabeth M. Barnes Reg. No. 35,059

Telephone No. (650) 225-4563

09157

PATENT TRADEMARK OFFICE